Exact Sciences Nets $17.6M from Public Offering

The firm will use the proceeds from the offering for product development efforts and to further its efforts to obtain US Food and Drug Administration clearance of its stool-based DNA colorectal cancer screening product.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories